Form 4: Celcuity Inc. Director David Dalvey Acquires Stock Options

Director David Dalvey of Celcuity Inc. reports the acquisition of stock options in a recent Form 4 filing.

Summary

• David Dalvey, a director of Celcuity Inc., filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on May 19, 2025.
• Dalvey acquired 14,048 stock options with an exercise price of $10.69.
• The options vest on April 30, 2026, or the date of the company's 2026 Annual Meeting of Stockholders, and expire on May 19, 2035.
• The filing was signed on Dalvey's behalf by Griffin D. Foster, as Attorney-in-Fact, pursuant to a Power of Attorney.
• A Power of Attorney document is included, authorizing Griffin D. Foster, Jonathan R. Zimmerman, Sheremy R. Anderson, and Amra Hoso to act on Dalvey's behalf for SEC filings related to Celcuity Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing related to stock option grants. While option grants can be seen as a positive sign of alignment between management and shareholders, the document itself is purely informational.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the vesting of the options is tied to the 2026 Annual Meeting of Stockholders.

Industry Context

Form 4 filings are a routine part of regulatory compliance for publicly traded companies and their insiders. They provide transparency into the transactions of company directors and officers, which can be useful for investors.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors and officers in publicly traded companies.
• The terms of the options, such as the exercise price, vesting schedule, and expiration date, are generally aligned with industry standards and company-specific performance goals.
• Comparing the option grants to those of similar companies in the biotechnology sector would provide a more detailed assessment.

Stakeholder Impact

• Shareholders may view the stock option grant as a sign of confidence from the director in the company's future prospects.
• The grant aligns the director's interests with those of the shareholders, as the value of the options is tied to the company's stock price.

Key Dates

Keywords

Form 4, Celcuity Inc., stock options, David Dalvey, director, acquisition, insider trading, SEC filing, Power of Attorney